logo

Your gate­way

to finance

and inno­va­tion

in Cen­tral Europe

Gen­eral

Third Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 1718 Octo­ber 2013

Reg­is­ter

Reg­is­tra­tion for this event has been closed.

Agenda

This year’s theme:

“Cap­i­tal, Man­age­ment & Col­lab­o­ra­tion: local & global perspectives”

Agenda cor­rect on 16 Octo­ber 2013

16 Octo­ber 2013

18.3020.30

Drinks and early reg­is­tra­tion opens

17 Octo­ber 2013

MAIN CON­FER­ENCE STARTS

08.00 Reg­is­tra­tion Opens

09.30

Wel­come
Leszek Grabar­czyk, The National Cen­tre for Research and Devel­op­ment; NCBR (Poland)

Roland Kozlowski, LSBC (Poland)

9.45 Ses­sion: Pri­vate and Pub­lic VC Investment

Chair: Oliver Mur­phy, Deloitte (PL)

9.45

Talk: Euro­pean VC and invest­ment trends

Kevin John­son, Index Ven­tures (CH)

10.15

Talk: The Euro­pean Invest­ment Fund as a fund of funds

Ralf Emmerich, EIF (B)

10.45

Talk: How to lever­age pri­vate invest­ments with pub­lic funding

Krzysztof Sen­ger Deloitte (PL)

11.15 Cof­fee & Networking


11.45 Ses­sion: Private-​public part­ner­ship and its role in ini­ti­at­ing the invest­ment cycle

Chair: Oliver Mur­phy, Deloitte (PL)

11.45

Talk: Pri­vate Pub­lic Part­ner­ship: Bridge VC

Leszek Grabar­czyk, The National Cen­tre for Research and Devel­op­ment; NCBR (Poland)

12.00

Talk: The role of the Pol­ish Agency for Enter­prise Devel­op­ment in fund­ing inno­va­tion.
Michal Banka, The Pol­ish Agency for Enter­prise Devel­op­ment (Poland)

12.15

Pub­lic approaches to sup­port­ing life sci­ences in the UK lessons for Cen­tral Europe:

Mark Tre­herne UKTI (UK)

12.30

Panel Dis­cus­sion: The pros and cons of Pub­lic Pri­vate Part­ner­ship and its Role in Assist­ing Devel­op­ment of Life Sci­ences Businesses

Mod­er­a­tor: Oliver Murphy

Derek Jones, Babra­ham Research Cam­pus (UK)

Leszek Grabar­czyk, The National Cen­tre for Research and Devel­op­ment; NCBR (PL)

Ralf Emmerich, EIF (B)

Mark Tre­herne UKTI (UK)


13.15 Net­work­ing lunch

14.15 Ses­sion: Inter­na­tional Collaboration

Chair: Mark Tre­herne

Talk: Case study – Win­ning the deal and sub­se­quent collaboration

Phil Gould; Jadara Pharma (UK)

14.45

Panel dis­cus­sion: Win­ning the deal and sub­se­quent col­lab­o­ra­tion the do’s and don’ts

Mark Tre­herne

Phil Gould; Jadara Pharma (UK)

Pawel Przewie­z­likowski, Selvita (Poland)

Barry Kenny, Hep­tares (UK)

Johannes Zanzinger, Boehringer Ingel­heim Pharma GmbH & Co. (KG)

Charles Brig­den, Amgen (US)

15.30

TEA & Networking

16.15

Panel Dis­cus­sion: The far east scene and gain­ing invest­ment from the far east it is pos­si­ble for cap­i­tal inten­sive CE businesses

Mod­er­a­tor:

Philip Gould (UK)

Ajoy Khand­he­ria, Global Asia Part­ners (India)

Sven Rohmann, Bur­rill & Com­pany, Bur­ril (D)

Jian Cao, RTC Inno­va­tion Ltd (UK)

Stephen Rhind, Propharma Part­ners (UK)

17.00

Con­fer­ence close for the day

19.15

Net­work­ing drinks and Con­fer­ence Dinner

18 Octo­ber 2013

8.00

Round table dis­cus­sion alter­na­tive forms of pro­tect­ing phar­ma­ceu­ti­cal intel­lec­tual prop­erty + break­fast for around 25 people

Prze­mysław Walasek, Tay­lor Wess­ing (Poland)

Ses­sion Starts 9.15 Bio­log­ics – an oppor­tu­nity for Cen­tral Europe

Chair: Bar­tosz Wal­ter, Pol­ish Acad­emy of Sci­ences (PL)

9.15

Talk: The Bio­log­ics Scene

Maria Bednarek, Med­imune (US/​UK)

9.45

Panel Dis­cus­sion: Bio­log­ics the future an oppor­tu­nity for Cen­tral Europe; inno­va­tion or collaboration?

Mod­er­a­tor: Roland Kozlowski

Kevin FitzGer­ald; Activ­iomics (UK)

Maria Bednarek, Med­imune (US/​UK)

Johannes Zanzinger, Boehringer Ingel­heim Pharma GmbH & Co. (KG)

Piotr Zien, Pol­pharma (PL)

10.30

Organ­i­sa­tion Presentations

Kare Riis Nielsen

Talk: Biobased Indus­tries Con­sor­tium (Novozymes) (B)

Fer­enc Marofka; Euro­pean Com­mis­sion (B)

Talk: Hori­zon 2020: What is in for life sci­ences in Cen­tral Europe?

11.00

Cof­fee and networking

11.30

Com­pany presentations:

Chair: Bar­tosz Wal­ter, Pol­ish Acad­emy of Sci­ences (PL)

Pro­teon Sp. z o.o.

Blirt S.A.

Numed Sp. z o.o.

12.15

Panel dis­cus­sion: The big pic­ture – bring­ing it all together how to make money in life sciences.

Mod­er­a­tor: Roland Kozlowski

Antoine Papiernik, Sofinnova (France)

Marek Orlowski, Orenore (Poland)

John Mil­iad, NBGI Ven­tures (UK)

Bill Mason, Sage Health­care (UK)

13.15

Sum­ming up

Roland Kozlowski, LSBC (PL) & Oliver Mur­phy, Deloitte (PL)

13.30

Con­fer­ence close

Speak­ers

        • Antoine Papiernik
          Antoine Papiernik
        • Oliver Murphy
          Oliver Mur­phy
        • Roland Kozlowski
          Roland Kozlowski
        • Leszek Grabarczyk
          Leszek Grabar­czyk
        • Pawel Przewiezlikowski
          Pawel Przewie­z­likowski
        • John E. Milad
          John E. Milad
        • Mark Treherne
          Mark Tre­herne
        • Derek Jones
          Derek Jones
        • Kevin FitzGerald
          Kevin FitzGer­ald
        • Marek Orłowski
          Marek Orłowski
        • Phil Gould
          Phil Gould
        • Barry Kenny
          Barry Kenny
        • David Tapolczay
          David Tapol­czay
        • Sven Rohmann
          Sven Rohmann
        • Kevin Johnson
          Kevin John­son
        • Maria Bednarek
          Maria Bednarek
        • Dr. Ralf Emmerich
          Dr. Ralf Emmerich
        • Annita Westenbroek
          Annita West­en­broek
        • Mike Romanos
          Mike Romanos
        • Mark Bushfield
          Mark Bush­field
        • Johannes Zanzinger
          Johannes Zanzinger
        • Dr. Jian Cao
          Dr. Jian Cao
        • Ray Barlow
          Ray Bar­low
        • Przemysław Walasek
          Prze­mysław Walasek
        • Charles Bridgen
          Charles Brid­gen
        • Klaus Martin
          Klaus Mar­tin
        • Bill Mason
          Bill Mason
        • Stephen Rhind
          Stephen Rhind
        • Ferenc Marofka
          Fer­enc Marofka
        • Kåre Riis Nielsen
          Kåre Riis Nielsen
        • Krzysztof Senger
          Krzysztof Sen­ger
        • Michał Jasiorkowski
          Michał Jasiorkowski
        • Michał Bańka
          Michał Bańka
Antoine Papiernik

Antoine Papiernik

Antoine Papiernik is a Man­ag­ing Part­ner at Sofinnova Part­ners, which he joined in 1997. Antoine has been an ini­tial investor and active board mem­ber in pub­lic com­pa­nies like Acte­lion, Addex, Orexo, Novus­Pharma (then sold to CTI), Movetis (then sold to Shire) and Sten­tys, which went pub­lic respec­tively on the Zürich stock exchange, the Stock­holm stock exchange, the Milan Nuovo Mer­cato, the Bel­gium Stock Exchange and EuroNext Paris, in Cotherix (ini­tially NAS­DAQ listed, then sold to Acte­lion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aven­tis). He has also invested in and is a board mem­ber of pri­vate com­pa­nies MD Start, CoAxia, EOS, Main­stay and ReCor. Antoine has an MBA from the Whar­ton School of Busi­ness, Uni­ver­sity of Pennsylvania.

For 2012 and 2011, Antoine has been rec­og­nized on the Forbes “Midas List” of the top deal­mak­ers in life-​science and high-​tech ven­ture cap­i­tal. Antoine is one of the only Euro­peans on the list, and one of the few life-​science investors as well.


Oliver Murphy

Oliver Mur­phy

Oliver Mur­phy Part­ner Trans­ac­tion Advi­sory Ser­vicesO­liver is a grad­u­ate of the Uni­ver­sity of Man­ches­ter in Eco­nom­ics and Gov­ern­ment. He speaks flu­ent Pol­ish. Oliver has has a wide range of cor­po­rate finance, due dili­gence and restruc­tur­ing and inte­gra­tion expe­ri­ence within both the UK and Poland and spe­cialises in cross-​border trans­ac­tion sup­port engage­ments com­pris­ing large multi-​disciplinary, multi­na­tional teams.


Roland Kozlowski

Roland Kozlowski

Roland Kozlowski received a first class hon­ours degree from the Uni­ver­sity of Bath and a PhD from the Uni­ver­sity of Cam­bridge. He is a bioen­tre­pre­neur who has worked in the indus­try for approach­ing two decades. Roland has held a num­ber of oper­a­tional roles includ­ing most recently Chief Exec­u­tive Offi­cer and a founder of Lec­tus Ther­a­peu­tics Lim­ited (investor exit via asset sale to UCB in Q4, 2011), Chief Exec­u­tive Offi­cer and co-​founder of Sense Pro­teomic Lim­ited (trade sale to Procog­nia Lim­ited in Q1, 2003). In the mid 1990s Roland worked with Oxford Mol­e­c­u­lar PLC on their cor­ner­stone deal he nego­ti­ated with Yamanouchi Phar­ma­ceu­ti­cal Co., Ltd. Dur­ing his career Roland has gained con­sid­er­able trans­ac­tional expe­ri­ence rang­ing from com­pany sale, pur­chase, financ­ing and in– and out-​licensing and com­mer­cial­i­sa­tion of tech­nol­ogy. In the past Roland ran a Research Groups at the Uni­ver­sity of Oxford and Uni­ver­sity of Bris­tol where sub­se­quently he was a Vis­it­ing Indus­trial Pro­fes­sor. He has pub­lished and patented in the field of ion chan­nel phys­i­ol­ogy and phar­ma­col­ogy. Roland has served on the boards of a num­ber of com­pa­nies includ­ing the Bio-​Industry Asso­ci­a­tion in the UK. He remains a direc­tor of Lec­tus Ther­a­peu­tics Lim­ited and is presently non-​executive direc­tor of Lon­don Genet­ics Lim­ited which oper­ates in the per­son­alised med­i­cine space, Chief Strat­egy Offi­cer of BTM Mazowsze Sp. z o. o. a com­pany set up to com­mer­cial­ize inno­va­tion emerg­ing from the lead­ing life sci­ence research insti­tu­tions in Warsaw.


Leszek Grabarczyk

Leszek Grabar­czyk

Leszek Grabar­czyk Since April 2011 Deputy Direc­tor of the National Cen­tre for Research and Devel­op­ment – reshaped gov­ern­men­tal agency play­ing the main role in fund­ing applied research and sup­port­ing com­mer­cial­i­sa­tion of research results. Jan­u­ary 2009 – March 2011: direc­tor of the Depart­ment for Research Appli­ca­tions and Inno­va­tion, Min­istry of Sci­ence and Higher Edu­ca­tion, War­saw (main respon­si­bil­i­ties: fund­ing of projects and infra­struc­tures for R&D within oper­a­tional pro­grammes Inno­v­a­tive Econ­omy and Human Cap­i­tal, elab­o­ra­tion and imple­men­ta­tion of other pro­grammes sup­port­ing inno­va­tion, coor­di­na­tion and mon­i­tor­ing of activ­i­ties of other insti­tu­tions engaged in sup­port of R&D and inno­va­tion). July 2007 – Decem­ber 2008: deputy direc­tor of the National Cen­tre for Research and Devel­op­ment – NCRD (gov­ern­men­tal agency fund­ing R&D, estab­lished 1 July 2007). 20042007: in the Pol­ish Min­istry of Sci­ence and Higher Edu­ca­tion, Depart­ment of Sci­ence Strat­egy and Devel­op­ment; engaged inter alia in prepa­ra­tion of legal frame­work for NCRD, oper­a­tional pro­grammes Inno­v­a­tive Econ­omy and Human Cap­i­tal, elab­o­ra­tion and imple­men­ta­tion of the largest gov­ern­men­tal pro­gramme fund­ing R&D and inno­v­a­tive activ­i­ties – “Tech­nol­ogy Ini­tia­tive”. Grad­u­ated from the National School of Pub­lic Admin­is­tra­tion, Warsaw.


Pawel Przewiezlikowski

Pawel Przewie­z­likowski

Pawel Przewie­z­likowski, co-​founded Selvita in 2007 and is the Chief Exec­u­tive Offi­cer of the com­pany, respon­si­ble for strate­gic man­age­ment, busi­ness and cor­po­rate devel­op­ment. He is also the Chief Exec­u­tive of Bio­Cen­trum, Selvita’s daugh­ter com­pany. Mr. Przewie­z­likowski is a mem­ber of the Eco­nomic Coun­cil of the Mal­opol­ska (Krakow) region as well as of the Mal­opol­ska Inno­va­tion Coun­cil. From 1994 to 2007 he worked at ComArch, a Pol­ish infor­ma­tion tech­nol­ogy com­pany. As a man­age­ment board mem­ber since 1996, he was respon­si­ble for the divi­sions offer­ing solu­tions for the phar­ma­ceu­ti­cal, bank­ing, man­u­fac­tur­ing and ser­vices indus­tries and took part in the organic trans­for­ma­tion of a uni­ver­sity spin-​off to the largest organ­i­cally grown IT com­pany in Cen­tral and East­ern Europe, employ­ing over 2 700 peo­ple in 20 coun­tries. Dur­ing his time at ComArch in 19992000 he was also the co-​founder and the first CEO of Inte​ria​.pl, the third largest por­tal in Poland. Mr. Przewie­z­likowski holds an MBA from the joint pro­gram of the Uni­ver­sity of Teesside (United King­dom) and Krakow School of Eco­nom­ics (Poland) as well as mas­ter degree in com­puter sci­ence from AGH Tech­ni­cal Uni­ver­sity in Krakow.


John E. Milad

John E. Milad

John E. Milad has nearly 20 years’ expe­ri­ence in pri­vate equity, ven­ture start-​ups, cor­po­rate finance and the health­care indus­try. He is an Invest­ment Direc­tor of NBGI Ven­tures, a spe­cial­ist medtech invest­ment fund based in Lon­don. John serves on the boards of sev­eral port­fo­lio com­pa­nies in Europe and the US. He is also a mem­ber of the i4i selec­tion panel of the NHS National Insti­tute for Health Research and is an advi­sory board mem­ber of Con­nect Dig­i­tal Health.His pre­vi­ous roles include found­ing the advi­sory bou­tique Insight Cap­i­tal, serv­ing as CFO at Nitec Pharma, being a Spe­cial Advi­sor to Atlas Ven­ture and lead­ing health­care cor­po­rate finance trans­ac­tions at Nomura Inter­na­tional in Lon­don. He started his career as an invest­ment banker at Lehman Broth­ers in New York, fol­lowed by pri­vate equity invest­ment expe­ri­ence at Kirk­land Investors. John is a grad­u­ate of the Uni­ver­sity of Chicago.


Mark Treherne

Mark Tre­herne

Mark has been actively involved in the bio­phar­ma­ceu­ti­cal indus­try for 25 years and was a co-​founder and Chief Exec­u­tive of Cam­bridge Drug Dis­cov­ery Lim­ited, lead­ing the Company’s acqui­si­tion by Bio­Fo­cus plc, where he then became a Com­mer­cial Direc­tor, dri­ving sig­nif­i­cant growth of its prof­itable ser­vices busi­ness. Mark has now served on the Boards of 13 pri­vate and pub­lic bio­phar­ma­ceu­ti­cal com­pa­nies and is cur­rently on the Boards of Cycloflu­idic, Domain Ther­a­peu­tics, Pop­u­la­tion Genet­ics Tech­nolo­gies and Senexis. Dr Tre­herne has now helped raise more than £140 mil­lion for var­i­ous bio­phar­ma­ceu­ti­cal busi­nesses over the last decade. Mark was also for­merly Chair­man of ERBI Lim­ited, which is a not-​for-​profit organ­i­sa­tion that rep­re­sents the biotech­nol­ogy com­pa­nies based around Cam­bridge in the East of Eng­land. Mark ini­tially trained as a neu­ro­sci­en­tist and elec­tro­phys­i­ol­o­gist at Cam­bridge Uni­ver­sity. Mark joined the Life Sci­ence Invest­ment Organ­i­sa­tion as Chief Exec­u­tive, fol­low­ing its for­ma­tion by UK Trade and Investment.


Derek Jones

Derek Jones

Derek, as CEO of Babra­ham Bio­science Tech­nolo­gies, has brought a wealth of expe­ri­ence to the Babra­ham Research Cam­pus arguably the UK’s most suc­cess­ful bio-​incubator site. He has over 20 years’ in the phar­ma­ceu­ti­cal indus­try as both a sci­en­tist and in busi­ness and cor­po­rate devel­op­ment, with first-​hand expe­ri­ence of estab­lish­ing bio­med­ical ven­tures. Ini­tially a med­i­c­i­nal chemist with Merck, Derek moved into busi­ness and cor­po­rate devel­op­ment at Chi­ro­science, suc­cess­fully nego­ti­at­ing sev­eral multi mil­lion pound licens­ing agree­ments. In 2000, he co-​founded his first com­pany, BioW­is­dom, an IT/​Drug dis­cov­ery com­pany. Derek was appointed COO at Dan­io­Labs in 2002, a ther­a­peu­tics com­pany using zebrafish as a model organ­ism for drug dis­cov­ery, where he grew the com­pany from 4 to 34 employ­ees and raised around £10 mil­lion for VC backed com­pa­nies, before sell­ing Dan­io­Labs to Vas­tox, now Sum­mit Plc, for £15 mil­lion in 2007. He has an MBA from the Judge Busi­ness School, and is a Char­tered Direc­tor. Derek is also a mem­ber of the Cam­bridge Enter­prise Invest­ment Com­mit­tee which invests in early stage oppor­tu­ni­ties aris­ing from research at Cam­bridge University.


Kevin FitzGerald

Kevin FitzGer­ald

Kevin FitzGer­ald is a life-​sciences entre­pre­neur with a strong track record in the com­mer­cial exploita­tion of novel bio­log­ics tech­nolo­gies. As CEO for F-​star (a bi-​specific anti­body com­pany) Kevin raised €23m in two invest­ment rounds; the first co-​led by Merck Serono Ven­tures and MP Health­care Ven­ture Man­age­ment and the sec­ond led by SR One. While at F-​star, Kevin also secured sub­stan­tial com­mer­cial agree­ments with Merck Serono and with Boehringer Ingel­heim (the lat­ter deal being the 7th largest biotech-​to-​pharma deal of 2010). As a result, F-​star was voted onto the Fierce15 list for 2011, the only Euro­pean com­pany to be included on that list. Prior to this, Kevin was founder and CEO of Iso­genica (a ther­a­peu­tic pep­tide com­pany) where he secured deals with AZ, J&J, Amgen, Cen­to­cor, Pfizer, Wyeth, GE Health­care and many oth­ers. Kevin has also served as Chief Oper­at­ing Offi­cer for Immune Tar­get­ing Sys­tems (a T-​cell vac­cine com­pany) and he was among the found­ing sci­en­tists of Cam­bridge Anti­body Tech­nol­ogy. Kevin stud­ied for his PhD at the MRC Lab­o­ra­tory of Mol­e­c­u­lar Biol­ogy, Cam­bridge, in the lab­o­ra­tory of Sir Gre­gory Win­ter FRS and he was awarded an MBA with dis­tinc­tion from Aston Busi­ness School, Birmingham.


Marek Orłowski

Marek Orłowski

Dr. Orłowski was a Co-​Founder of Nepentes SA, a man­u­fac­turer and sup­plier of phar­ma­ceu­ti­cal prod­ucts. In his time with the com­pany, he served as as its Sales, Mar­ket­ing and R&D Vice Pres­i­dent. At the time of the company’s estab­lish­ment in 1991, he held the posi­tion of Mar­ket­ing Direc­tor. In 1995, he took the posi­tion of Vice-​President of the newly founded Nepentes Sp. z.o.o. (Ltd. Com­pany) and ran the com­pany until it went pub­lic and was sold to Sanofi-​Aventis for about €106M in 2010. In August 2007, he became Vice-​President of the Man­age­ment Board of Nepentes S.A. and since Sep­tem­ber 2010, was a mem­ber of the Man­age­ment Board. He was respon­si­ble for mar­ket­ing, sales, port­fo­lio cre­ation, strate­gic devel­op­ment and R&D. He nego­ti­ated dis­tri­b­u­tion con­tracts and coor­di­nated prod­uct launches in the mar­kets of East­ern Europe; from Rus­sia, through Poland, to Roma­nia. Today he is a board mem­ber and investor in var­i­ous life-​science projects in Poland, Canada and Israel.


Phil Gould

Phil Gould

Phil Gould is the CEO of Jadara Pharma Ltd – a busi­ness and tech­ni­cal con­sul­tancy set up to sup­port the growth of emerg­ing health­care com­pa­nies. Phil has a strong inter­est in work­ing with small, start up life com­pa­nies and the chal­lenges that these com­pa­nies face in the devel­op­ment of their busi­nesses. His present work involves aspects of tech­ni­cal and IP due dili­gence, work­ing with emerg­ing com­pa­nies on behalf of their investors, and sup­port­ing inter­na­tional R&D col­lab­o­ra­tions for a num­ber of clients.

Phil grad­u­ated from Hull Uni­ver­sity with a degree in chem­istry and then a PhD in phys­i­cal chem­istry and kinet­ics. He has a strong inter­est in drug dis­cov­ery and devel­op­ment and has worked in the area for over 30 years for both major phar­ma­ceu­ti­cal com­pa­nies such as Glax­o­SmithK­line and Pfizer, and also a num­ber of biotech­nol­ogy companies.

As an expe­ri­enced life sci­ence based non-​executive direc­tor, Phil has held board posi­tions at Ora­tol Ltd, Lec­tus Ther­a­peu­tics Ltd, Well Trav­elled Clin­ics and Brad­ford Phar­ma­ceu­ti­cals Ltd, and is cur­rently a non-​executive direc­tor of RedX Pharma Ltd. At RedX Pharma, Phil also chairs the Sci­en­tific Advi­sory Boards in anti-​infectives and oncol­ogy and is retained as a pro­grammes advisor.

Phil also con­tin­ues to work in the ‘not for profit’ health­care sec­tor, using his expe­ri­ence of pre­vi­ously being the Chief Busi­ness Offi­cer for the Liv­er­pool School of Trop­i­cal Med­i­cine, devel­op­ing its inter­na­tional R&D and big pharma col­lab­o­ra­tions, sup­ported by the Bill and Melinda Gates Foun­da­tion, in the areas of neglected disease.


Barry Kenny

Barry Kenny

Barry has over 25 years research and man­age­ment expe­ri­ence in the phar­ma­ceu­ti­cal and biotech­nol­ogy indus­try and is cur­rently Chief Busi­ness Offi­cer at Hep­tares Ther­a­peu­tics where he leads the Company’s licens­ing and busi­ness devel­op­ment activ­i­ties. He was pre­vi­ously Vice Pres­i­dent, Drug Dis­cov­ery at Takeda Cam­bridge UK with over­all respon­si­bil­ity for IND dis­cov­ery. Prior to this, he was Com­mer­cial Direc­tor at Par­a­digm Ther­a­peu­tics where he was respon­si­ble for sev­eral com­pany trans­form­ing deals and was also instru­men­tal in the sub­se­quent acqui­si­tion of Par­a­digm by Takeda in 2007. Barry co-​founded Cam­bridge Drug Dis­cov­ery (CDD) in 1997, and was Direc­tor of Busi­ness Devel­op­ment for Bio­fo­cus fol­low­ing its merger with CDD in 2001, estab­lish­ing a wide range of inter­na­tional deals and col­lab­o­ra­tions. Before this, he was at Pfizer Cen­tral Research and was respon­si­ble for the suc­cess­ful dis­cov­ery and pro­gres­sion of sev­eral drug can­di­dates into clin­i­cal devel­op­ment. He also spent eight years at Syn­tex Research Scot­land, where he com­pleted his PhD and post-​doctoral studies.


David Tapolczay

David Tapol­czay

Dr David Tapol­czay has 28 years expe­ri­ence of R&D man­age­ment; his past roles include joint world­wide head of chem­istry for Zeneca agro­chem­i­cals and senior man­ager of chem­i­cal devel­op­ment for Glaxo. He was respon­si­ble for the rapid growth of Cam­bridge Dis­cov­ery Chem­istry and was a key fig­ure in two suc­cess­ful sales of the com­pany ini­tially to Oxford Mol­e­c­u­lar and then Mil­len­nium Phar­ma­ceu­ti­cals. Post this last acqui­si­tion David was VP of Phar­ma­ceu­ti­cal Sci­ences with respon­si­bil­ity for over 230 sci­en­tists. On leav­ing Mil­len­nium David was a founder of Phar­mor­phix Ltd which was acquired by Sigma Aldrich Fine Chem­i­cals in August 2006. He has also been involved with the start up of 5 com­pa­nies all of which are still trad­ing and one of which has been AIM listed. He was most recently VP of Tech­nol­ogy Devel­op­ment for GSK phar­ma­ceu­ti­cals and is cur­rently the Chief Exec­u­tive Offi­cer of the Med­ical Research Coun­cil Tech­nol­ogy Group (MRCT).

David has an inter­na­tional rep­u­ta­tion in the phar­ma­ceu­ti­cal indus­try as well as an out­stand­ing aca­d­e­mic track record with a con­sid­er­able num­ber of patents and pub­li­ca­tions. He was a vis­it­ing Pro­fes­sor at Sus­sex Uni­ver­sity and has pre­vi­ously held the posi­tion of vis­it­ing lec­turer at Not­ting­ham, Read­ing and Durham Uni­ver­si­ties and a mem­ber of both the Tech­ni­cal Oppor­tu­ni­ties Panel and the User Panel of the EPSRC. In addi­tion he is a non exec­u­tive direc­tor for sev­eral biotech companies.


Sven Rohmann

Sven Rohmann

Sven Rohmann, MD, PhD, MBA

Gen­eral Man­ager Europe & Man­ag­ing Direc­tor Dig­i­tal Health

Bur­rill & Com­pany and Bur­rill Securities

Dr. Rohmann has a sci­en­tific, aca­d­e­mic back­ground in clin­i­cal med­i­cine and basic research. He spent 10 years at Merck Serono, which pro­vided him with a strong foothold in the phar­ma­ceu­ti­cal indus­try. His career exposed him to pre-​clinical, clin­i­cal devel­op­ment as well as mar­ket­ing, busi­ness and cor­po­rate devel­op­ment. Dur­ing his tenure at Merck he was involved in the suc­cess­ful licens­ing of Erbitux from ImClone and the estab­lish­ment of Merck Oncol­ogy. Dr. Rohmann joined Bur­rill & Com­pany in 2010.

Prior to join­ing Bur­rill & Com­pany, Dr. Rohmann worked as Ven­ture Cap­i­tal Fund Man­ager for Novar­tis Pharma AG, and as Man­ag­ing Part­ner at Nex­tech Ven­ture, both Switzer­land. In addi­tion, Dr. Rohmann served as CEO of two Euro­pean biotech start-​ups and gained board expe­ri­ence at three SME’s in Germany.

Dr. Rohmann’s unique blend of sci­en­tific, pharma/​biotech and ven­ture knowl­edge, an exten­sive net­work of con­tacts among health care providers as well as aca­d­e­mic and gov­ern­ment research admin­is­tra­tors, a thor­ough knowl­edge of Euro­pean research and reg­u­la­tory poli­cies, and a sig­nif­i­cant expe­ri­ence in global as well as Euro­pean part­ner­ing sig­nif­i­cantly extends the invest­ment reach of Bur­rill & Com­pany towards Europe.

Dr. Rohmann received his MD from the Uni­ver­sity of Mainz, Ger­many, and his PhD from the Eras­mus Uni­ver­sity, Rot­ter­dam, Netherlands.


Kevin Johnson

Kevin John­son

Kevin John­son is a Part­ner at Index Ven­tures work­ing out of the Lon­don office.Prior to that he was CEO of Pan­Genet­ics, an anti­body devel­op­ment com­pany based in the Nether­lands, and one of the Index Ven­tures port­fo­lio. Kevin was one of the team at Cam­bridge Anti­body Tech­nol­ogy (CAT), head­ing up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Direc­tor and Chief Tech­nol­ogy Officer.Kevin led both the devel­op­ment of CAT’s plat­form tech­nolo­gies, and also their appli­ca­tion to the dis­cov­ery of a num­ber of human anti­bod­ies cur­rently in clin­i­cal devel­op­ment. Two of these are now mar­keted, Humira (Abbott Phar­ma­ceu­ti­cal) and Benlysta (HGS, GSK). He was also part of the man­age­ment team that floated CAT on the Lon­don Stock Exchange (main market).Kevin grad­u­ated in Mol­e­c­u­lar Biol­ogy from Edin­burgh Uni­ver­sity and has a PhD in Pathol­ogy from Cam­bridge University.


Maria Bednarek

Maria Bednarek

Maria Bednarek­Maria is Prin­ci­pal Sci­en­tist, Pep­tide Plat­form, at Med­Im­mune Ltd, UK with over 30 years of research and man­age­ment expe­ri­ence in acad­e­mia and pharma R&D. She has strong inter­est in the dis­cov­ery and devel­op­ment of drugs tar­get­ing meta­bolic dis­eases. After 20 years at Merck Research Lab­o­ra­to­ries (USA) she joined Med­Im­mune, the global bio­log­ics R&D unit of AstraZeneca, in 2009 where she has estab­lished and now leads the ther­a­peu­tic pep­tide dis­cov­ery team.A chem­istry grad­u­ate from the Uni­ver­sity of Lodz and Gdansk (PhD), Maria sub­se­quently con­ducted research at Case West­ern Reserve Uni­ver­sity and Har­vard Med­ical School. She is an inter­na­tion­ally rec­og­nized sci­en­tist with a con­sid­er­able pub­li­ca­tion and patent record. Maria is an active mem­ber of the Coun­cil of the Amer­i­can Pep­tide Soci­ety and orga­nizer of sci­en­tific conferences.


Dr. Ralf Emmerich

Dr. Ralf Emmerich

Dr. Ralf Emmerich is Invest­ment Man­ager at the Euro­pean Invest­ment Fund, which he joined in 2011. At EIF, he is mainly focussing on fund-​of-​funds invest­ments under the ERP-​EIF Dach­fonds man­date into Life Sci­ences VC funds and is as such rep­re­sent­ing EIF as advisory/​supervisory board mem­ber in many VC funds. Prior to EIF, Ralf Emmerich spent six years as man­ag­ing con­sul­tant at Capgem­ini Con­sult­ing, where he led strate­gic con­sult­ing projects for pharma com­pa­nies and pub­lic research insti­tu­tions in the areas of strat­egy devel­op­ment, merger&acquisition, post-​merger inte­gra­tion, tech­nol­ogy trans­fer and organ­i­sa­tion & process devel­op­ment. Before this, he worked for five years as invest­ment man­ager at Aure­lia Pri­vate Equity respon­si­ble for Life Sci­ences invest­ments and as equity ana­lyst at Con­cord Effek­ten, an invest­ment bank in Frank­furt. Ralf Emmerich received his Ph.D. at the Swiss Fed­eral Insti­tute of Tech­nol­ogy Zurich and stud­ied bio­chem­istry at Uni­ver­sity of Bayreuth and Uni­ver­sity VII, Paris, as well as eco­nom­ics at the aca­d­e­mic Busi­ness School Lahr.


Annita Westenbroek

Annita West­en­broek

Since 1 March 2010 Annita West­en­broek is direc­tor of the Dutch Biore­fin­ery Clus­ter, a coop­er­a­tion between the Dutch bio-​based indus­tries, and since 1 Octo­ber 2011 she is also employed as direc­tor inno­va­tions at the Royal Asso­ci­a­tion of Dutch Paper and Board Industries.

Cur­rently Annita West­en­broek is Coor­di­na­tor Pro­gram­ming in the prepa­ra­tion of BRIDGE, the Biobased Indus­tries PPP under Hori­zon 2020.Annita stud­ied Chem­i­cal Engi­neer­ing and received her PhD on the basis of a project towards refin­ing of paper mak­ing fibres. She has been employed for 11 years at Wagenin­gen UR, of which the last years being respon­si­ble for coor­di­na­tion of the research group focus­ing towards the pulp & paper indus­try. From 2006 until 2011 she was pro­gram man­ager at the Cen­tre of Com­pe­tence Paper and Board. At national level she coor­di­nated the col­lec­tive research on fibre raw mate­ri­als for the Dutch paper and board indus­try and the Pro­gram ‘Biore­fin­ery’ of the Dutch Energy Tran­si­tion in the Paper Chain.


Mike Romanos

Mike Romanos

Mike Romanos is CEO and founder of Crescendo Bio­log­ics Ltd, a VC-​backed Cam­bridge based com­pany that has devel­oped an inno­v­a­tive trans­genic plat­form for gen­er­at­ing human sin­gle domain anti­body ther­a­peu­tics. He has 25 years’ biotech and phar­ma­ceu­ti­cal indus­try expe­ri­ence in bio­logic and NCE drug dis­cov­ery across sev­eral ther­a­peu­tic areas, start­ing with Well­come Biotech, an early pio­neer in UK biotech­nol­ogy, in the 1980s.Previous to his cur­rent role, Mike held lead­er­ship posi­tions for over 10 years in Glax­o­SmithK­line R&D, build­ing and man­ag­ing global Dis­cov­ery organ­i­sa­tions that made a major impact in tar­gets, tech­nol­ogy and pipeline projects. In par­tic­u­lar, Mike played a key role in estab­lish­ing GSK’s anti­body lead dis­cov­ery capa­bil­ity which gen­er­ated a pipeline of in-​house mon­o­clonal anti­bod­ies, sev­eral of which are in clin­i­cal development.Mike holds a degree in Nat­ural Sci­ences from Cam­bridge Uni­ver­sity, a PhD in Mol­e­c­u­lar Virol­ogy from Impe­r­ial Col­lege, and under­took post­doc­toral research in Virol­ogy at the MRC’s National Insti­tute for Med­ical Research and in Yeast Biotech­nol­ogy at Leices­ter Bio­cen­tre. He is cur­rently a panel mem­ber of the MRC’s Devel­op­men­tal Path­way Fund­ing Scheme, which funds trans­la­tional stud­ies through pre­clin­i­cal and early clin­i­cal devel­op­ment, and a Fel­low of the Soci­ety of Biology.


Mark Bushfield

Mark Bush­field

Mark is a biol­o­gist with over 20 years of research and man­age­ment expe­ri­ence in Pharma, Biotech­nol­ogy and Life­sciences R&D. After com­plet­ing a PhD in Cel­lu­lar Sig­nalling, Mark spent 4 years study­ing sig­nal trans­duc­tion in New York and Glas­gow before join­ing Pfizer in 1990. He took on increas­ing respon­si­bil­ity for tech­nol­ogy and ther­a­peu­tic area research over a 7 year period at Pfizer. In 1997, Mark co-​founded Cam­bridge Drug Dis­cov­ery Lim­ited to pro­vide high-​throughput lead dis­cov­ery ser­vices to major Pharma and Biotech­nol­ogy com­pa­nies. CDD built a port­fo­lio of IP and col­lab­o­ra­tions and was sold to Bio­Fo­cus in 2001 for £28 mil­lion. After a 2-​year period as Biol­ogy Direc­tor of Bio­Fo­cus, Mark was appointed Research Direc­tor of Cell­tech and then VP of Research fol­low­ing the acqui­si­tion of Cell­tech by UCB in 2004, with dis­cov­ery research respon­si­bil­ity span­ning 4 research sites in the UK, Bel­gium and Ger­many. Mark joined Abcam in Novem­ber 2008 as Sci­en­tific Direc­tor and leads prod­uct devel­op­ment and man­u­fac­tur­ing and sci­en­tific busi­ness development.


Johannes Zanzinger

Johannes Zanzinger

Global Head, Car­dioMeta­bolic Busi­ness Devel­op­ment and Licensing

Boehringer Ingel­heim Pharma GmbH & Co KGJo­hannes leads Global Busi­ness Devel­op­ment and Licens­ing for Car­diometa­bolic Dis­eases within the Ther­a­peu­tic Alliances & Strate­gic Part­ner­ships (TASP) func­tion at Boehringer Ingel­heim. In addi­tion, he acts as an adjunct Pro­fes­sor of Phys­i­ol­ogy at the Uni­ver­sity of Ulm, Germany.Johannes gained sci­ence and R&D man­age­ment expe­ri­ence across mul­ti­ple dis­ease areas in acad­e­mia and indus­try, at Pfizer (UK) and Boehringer Ingel­heim before tak­ing on his role in Busi­ness Devel­op­ment & Licens­ing in the same com­pany in 2006.Johannes Zanzinger was trained in Ani­mal Sci­ences and Biol­ogy at the Uni­ver­sity of Hohen­heim in Ger­many, and held aca­d­e­mic posi­tions at the Med­ical Fac­ul­ties of the Uni­ver­si­ties of Freiburg and Hei­del­berg until 1998.


Dr. Jian Cao

Dr. Jian Cao

Dr. Jian CaoWith mul­ti­dis­ci­pline knowl­edge in Account­ing & Finances at Tian­jin Uni­ver­sity of Com­merce (BSc), Com­puter Sci­ence at Uni­ver­sity of Birm­ing­ham (MSc) and Mechan­i­cal Engi­neer­ing at Uni­ver­sity of Birm­ing­ham (PhD), Jian Cao founded RTC Inno­va­tion Ltd in 2009 and plays lead­ing roles in tech­nol­ogy trans­fer, technology-​based spin-​out. Before estab­lish­ing RTC Inno­va­tion, Jian worked as research fel­low at the Uni­ver­sity of Birm­ing­ham for a Euro­pean Union FP6 Inte­grated Project on Mass-​Manufacture of Miniature/​Micro Prod­ucts, coop­er­ated with EMPA, Switzer­land. Jian has been involved in research work since 2002, for Corus, UK, Israel Air­craft Indus­tries, IMRA, Japan, Shougang Research Insti­tute of Tech­nol­ogy, China etc. In 1998, Jian worked as senior accoun­tant in China Aero­space Sci­ence and Tech­nol­ogy Cor­po­ra­tion after grad­u­ated from his first degree in China.Jian has made and led in two ven­ture cap­i­tal invest­ments recently, and sits on the boards as direc­tors of the fol­low­ing two com­pa­nies: Oxford Multi Spec­tral Ltd and Oxford Vacmedix HK ltd.


Ray Barlow

Ray Bar­low

Ray Bar­low is cur­rently a deal lead in Amgen’s Strat­egy and Cor­po­rate Devel­op­ment team. In his Role, Ray has spe­cial respon­si­bil­ity for Amgen’s Euro­pean business.

Ray has expe­ri­ence in deal mak­ing in large Pharma, pub­lic and pri­vate biotech­nol­ogy com­pa­nies, start-​up envi­ron­ments and as the owner of his own busi­ness­Ray has nego­ti­ated and closed all types of agree­ments, includ­ing: acqui­si­tion, equity invest­ment, out-​licensing, in-​licensing, (co)development, (co)marketing, (co)promotion, option, sup­ply, qual­ity, man­u­fac­tur­ing and IP assign­ment agree­mentsRay started his career with AstraZeneca tran­si­tion­ing from R&D into Cor­po­rate Busi­ness Devel­op­ment at the Lon­don HQ over an 11-​year period.

Dur­ing 6 years of Cor­po­rate Devel­op­ment, Ray was respon­si­ble for a num­ber of exter­nal­iza­tion and regional expan­sion projects (includ­ing China and Russia/​CEE), as well as acqui­si­tion and licens­ing projects in mul­ti­ple Ther­apy Areas.

Ray then became Regional Busi­ness Direc­tor for Cen­tral and East­ern Europe and Rus­sia, where he man­aged a regional team respon­si­ble for deliv­er­ing a con­tri­bu­tion of ca. $200M from 14 prod­ucts in 14 countries.

After 11 years at AstraZeneca, Ray joined the sell-​side of the indus­try and became Head of Busi­ness Devel­op­ment for the pri­vate com­pany Micro­science Ltd, which was sold to Emer­gent BioSo­lu­tions Inc. Ray was appointed VP of BD for Emer­gent and, in addi­tion to num­ber of com­pleted licens­ing deals, he was also involved in the list­ing of Emer­gent on NASDAQ.

In July 2006, Ray set up his own busi­ness “BD Solu­tions Ltd”, which spe­cial­ized in all aspects of Cor­po­rate and Busi­ness Devel­op­ment. He advised a range of clients (rang­ing from Japan­ese majors to Uni­ver­sity start-​ups) from diverse geo­gra­phies on cor­po­rate devel­op­ment and coun­try entry projects. Ray also worked on fundrais­ing for start-​up com­pa­nies as interim CEO.

In April 2010, Ray joined Cru­cell NV in the Nether­lands and was one of the senior BD team that was involved with the sale of Cru­cell for $2.3Bn to John­son & John­son in Q1 2011.

Post acqui­si­tion, Ray took on respon­si­bil­ity for all dif­fer­ent BD activ­i­ties for immunotherapy-​based deals for Crucell/J&J. As part of this he had spe­cial respon­si­bil­ity for strate­gic invest­ments and rela­tion­ships in Tai­wan and Australia.

Ray joined Amgen on June 1st 2012. He is based in Zug, Switzerland.

Ray has a PhD in Chem­istry (summa cum laude) from Man­ches­ter Uni­ver­sity, UK and a MBA with dis­tinc­tion form the Man­ches­ter Busi­ness School, UK.


Przemysław Walasek

Prze­mysław Walasek

Prze­mysław Walasek grad­u­ated from the Euro­pean Uni­ver­sity of Viad­rina in Frank­furt (Oder) and Adam Mick­iewicz Uni­ver­sity in Poznan.

He is respon­si­ble for Intel­lec­tual Prop­erty in Tay­lor Wess­ing e|n|w|c.

He has exten­sive expe­ri­ence in advis­ing clients regard­ing all legal aspects of e-​business, new tech­nolo­gies, copy­rights, includ­ing entre­pre­neurs spe­cial­is­ing in on-​line. He rep­re­sents clients in cases regard­ing inter­net domains and breaches in coded TV secu­rity sys­tems. He has taken part in many inter­net start-​ups and advised entre­pre­neurs on copy­rights fees to organ­i­sa­tions. He also pro­vides legal ser­vices regard­ing com­mer­cial trans­ac­tions and sup­ports rel­e­vant cor­po­rate issues.

He spe­cialises in copy­rights, e-​business and cor­po­rate issues.

He is not only an author of var­i­ous pub­li­ca­tions regard­ing Intel­lec­tual Prop­erty Law, IT and e-​business but also Prze­mek is a lec­turer at many rel­e­vant and top­i­cal conferences.He has an excel­lent com­mand of both Ger­man and English


Charles Bridgen

Charles Brid­gen

Charles Brid­gen is the Euro­pean Busi­ness Devel­op­ment & Licens­ing Direc­tor for Amgen Inter­na­tional. In this role he has sup­ported many of Amgen’s recent global M&A trans­ac­tions includ­ing the $1.16B acqui­si­tion of Micromet, a biotech­nol­ogy com­pany founded in Ger­many and the acqui­si­tion of Mustafa Nevzat Phar­ma­ceu­ti­cals, a pri­vately held Turk­ish com­pany. He is also respon­si­ble for exter­nal R&D part­ner­ships in Europe includ­ing East­ern Europe and Russia.Having joined Amgen in 2004 as Ther­a­peu­tic Area Lead for Oncol­ogy, his most recent role was Exec­u­tive Med­ical Direc­tor for the UK & Ire­land where he led Amgen’s R&D efforts in this region. Prior to join­ing Amgen, Charles worked for Eli Lilly & Com­pany as a Clin­i­cal Research Physi­cian. Before join­ing indus­try, Charles trained as a sur­geon in the UK’s National Health Ser­vice work­ing in aca­d­e­mic teach­ing hos­pi­tals in Lon­don. He is a Fel­low of the Royal Col­lege of Sur­geons in Eng­land, a Mem­ber of the Fac­ulty of Phar­ma­ceu­ti­cal Med­i­cine of the Royal Col­lege of Physi­cians and holds an MBA from Colum­bia & Lon­don Busi­ness Schools.


Klaus Mar­tin

Klaus Mar­tin is the Senior Direc­tor of Pol­pharma Bio­log­ics lead­ing its global busi­ness and prod­uct and devel­op­ment activ­i­ties. With his broad expe­ri­ence in strat­egy and devel­op­ment of Biosim­i­lars and Bio­bet­ters. Klaus joined Pol­pharma to set up its Bio­log­ics busi­ness in Octo­ber 2010. Prior to Pol­pharma, for eight years he held global man­age­ment posi­tions at San­doz Bio­phar­ma­ceu­ti­cals, first as Devel­op­ment Project Leader, e.g. for San­doz’ fil­gras­tim and, a.i. for their rit­ux­imab biosim­i­lars, then as Head of Global Pre-​clinical and Clin­i­cal devel­op­ment and finally as Head of BD&L and Port­fo­lio Man­age­ment as a mem­ber of the Bio­phar­ma­ceu­ti­cals Exec­u­tive Com­mit­tee. His teams helped bring to the mar­ket San­doz’ first three biosim­i­lars in the EU, US and Japan.Klaus is a bio­chemist by train­ing and holds a PhD in Pathol­ogy from the Uni­ver­sity of Cam­bridge. Before join­ing the phar­ma­ceu­ti­cal indus­try, he spent three years as a strat­egy con­sul­tant with OC&C advis­ing inter­na­tional clients in a vari­ety of industries.


Bill Mason

Bill Mason

Dr. Bill Mason is an Exec­u­tive Direc­tor of the Sage Group based in USA and Europe. He is also a non-​executive Chair­man or Board Direc­tor of sev­eral EU and US high tech­nol­ogy pri­vate and/​or pub­licly quoted (UK and US) com­pa­nies in health­care and bio­sciences. He has con­sid­er­able expe­ri­ence in the pub­lic and pri­vate sec­tors, span­ning the suc­cess­ful strate­gic and com­mer­cial devel­op­ment and value real­iza­tion of high tech­nol­ogy life sci­ence– and health­care– focused indus­tries. These include phar­ma­ceu­ti­cal, biotech­nol­ogy, med­ical tech­nol­ogy and diag­nos­tics com­pa­nies, where he has worked with pri­vate equity and insti­tu­tional investors, VC funds and cor­po­rate finance firms in the life sci­ence and health care domains.Dr. Mason has a strong his­tory of found­ing, fund­ing, devel­op­ing, turn­ing around and exit­ing from a num­ber of com­pa­nies in this space, as well as work­ing with well-​established, more mature com­pa­nies. He has con­sid­er­able expe­ri­ence of com­mer­cial devel­op­ment of health­care busi­nesses, in respect of sales and mar­ket­ing and dis­tri­b­u­tion routes to rel­e­vant mar­kets, as well as the reg­u­la­tory require­ments to take pro­grams to com­mer­cial realization.He has led and been actively involved with a num­ber of IPOs and sec­ondary fund­ings (includ­ing PIPEs) in pub­lic mar­kets (LSE, NAS­DAQ) in addi­tion to numer­ous fund­ing activ­i­ties for pri­vate equity com­pa­nies. Dr. Mason has strong man­age­ment, trans­ac­tional and financ­ing expe­ri­ence with both pri­vate equity– and pub­licly– funded com­pa­nies. He is a highly moti­vated and orga­nized indi­vid­ual with a good track record in devel­op­ing inno­v­a­tive advanced tech­nol­ogy busi­nesses, and real­iz­ing share­holder value via trade sale or flota­tion, hav­ing been involved in more than 75 M&A, licens­ing deals and financings.


Stephen Rhind

Stephen Rhind

Stephen Rhind is a Com­mer­cial Con­sul­tant at ProPharma Part­ners Ltd. He has around 30 years of expe­ri­ence in the pharma-​biotech sec­tor, span­ning Europe, the US and Asia. As a cur­rent con­sul­tant he has a num­ber of Asian Clients in Sin­ga­pore as well as work­ing inde­pen­dently as a con­sul­tant for a Tokyo based port­fo­lio com­pany of Mit­sui & Co., Global Invest­ment Ltd.

Pre­vi­ously Stephen has spent nearly 7 years in Asia. As Senior Vice Pres­i­dent, Cor­po­rate Devel­op­ment at S*BIO Pte Ltd, he was respon­si­ble for play­ing a sig­nif­i­cant role in the exe­cu­tion of 2 major deals totalling in excess of $660m and which received a peer reviewed indus­try award for the most suc­cess­ful bio-​partnership in Asia in 2009. In these deals upfronts and related pay­ments of more than $45m were received. Addi­tion­ally he has sup­ported the CEO of S*BIO Pte Ltd in the rais­ing of $60m of pri­vate finance.

Stephen obtained his PhD in Bio­chem­istry from Cam­bridge Uni­ver­sity hav­ing entered the biotech indus­try in 1983 and has worked in 3 pub­lic and 1 pri­vate bio­phar­ma­ceu­ti­cal companies.


Ferenc Marofka

Fer­enc Marofka

Project Offi­cer – Euro­pean Com­mis­sion, DG Research & Inno­va­tion­Fer­enc is a Project Offi­cer at DG Research & Inno­va­tion, in the Health Direc­torate. He man­ages calls and mon­i­tors the sub­se­quent projects in the domain of health research with a focus on advanced ther­a­pies and sys­tems med­i­cine. He also con­tributes to EU’s health research pol­icy in the fields of inno­va­tion, SMEs and under­per­for­mance of new mem­ber states.Ferenc holds a degree in eco­nom­ics and fol­lowed courses in med­i­cine as well. Prior to join­ing the Euro­pean Com­mis­sion in 2008, he worked for Hun­gar­ian SMEs in the pharma sec­tor. His career at the Com­mis­sion started in DG Inter­nal Mar­ket and he has moved to health research in 2012.


Kåre Riis Nielsen

Kåre Riis Nielsen

Kåre Riis Nielsen is Direc­tor of Euro­pean Affairs. Kåre is respon­si­ble for Novozymes’ pub­lic affairs and media rela­tions in Europe. He joined Novozymes in 2009. Prior to that he has been an inde­pen­dent con­sul­tant and held posi­tions in the World Bank, United Nations and the Nordic Coun­cil of Ministers.


Krzysztof Senger

Krzysztof Sen­ger

Senior Man­ager in R&D and Gov­ern­ment Incen­tives Poland­Krzysztof has over 11 years of pro­fes­sional expe­ri­ence in advis­ing pub­lic author­i­ties and pri­vate com­pa­nies in course of imple­men­ta­tion of the EU funds and finan­cial instru­ments. Krzysztof spe­cial­izes in cost ben­e­fit analy­sis, fea­si­bil­ity stud­ies, prepa­ra­tion of project doc­u­men­ta­tion for large infra­struc­ture projects (mainly R&D). He has been rais­ing funds for invest­ments, research and human resources devel­op­ment and has been also involved in con­duct­ing nego­ti­a­tions with the Euro­pean Com­mis­sion, coop­er­a­tion with the Euro­pean Invest­ment Bank and the Jaspers Initiative.


Michał Jasiorkowski

Michał Jasiorkowski

Michał Jasiorkowski works in National Cen­ter for Research and Devel­op­ment, where he is respon­si­ble for design­ing and imple­men­ta­tion of new types of public-​private invest­ment pro­grams, which cur­rently com­prise: BRIdge VC (pro­gram run jointly with lead­ing Pol­ish and for­eign VC funds), BRIdge Men­tor (pro­gram run jointly with lead­ing con­sult­ing com­pa­nies) and BRIdge α (set of invest­ment vehi­cles for early-​stage R&D Project).Michał has over 11 years pro­fes­sional expe­ri­ence gained in both pub­lic and pri­vate sec­tor. He is also Cer­ti­fied Infor­ma­tion Sys­tems Audi­tor (CISA), as well as grad­u­ate of Cra­cow Uni­ver­sity of Eco­nom­ics and War­saw School of Economics.


Michał Bańka

Michał Bańka

Michał Bańka worked at the Min­istry of Econ­omy to man­age and medi­ate imple­men­ta­tion of sev­eral EU funded pro­grams. Since 2006 his respon­si­bil­i­ties have included run­ning the finan­cial depart­ments of three Pro­grams: (1) Improv­ing the Com­pet­i­tive­ness of Enter­prises, (2) Inno­v­a­tive Econ­omy and (3) Infra­struc­ture and Envi­ron­ment. He has held the posi­tions of Deputy Direc­tor, and from 2012 Direc­tor of the Depart­ment of Busi­ness Envi­ron­ment Insti­tu­tion Sup­port of the Pol­ish Agency for Enter­prise Devel­op­ment. His respon­si­bil­i­ties include: (1) Pro­vid­ing sup­port for busi­ness incu­ba­tors in find­ing inno­v­a­tive ideas and cap­i­tal input for “Start-​ups”, (2) Sup­port of the ‘Busi­ness Angels’ Net­work, (3) Sup­port for Busi­ness Envi­ron­ment Insti­tu­tions, (4)

Orig­i­na­tor, Loan fund man­agers for micro and small enter­prises with the par­tic­i­pa­tion of busi­ness angel or ven­ture cap­i­tal fund.

Financ­ing of advi­sory ser­vices that are nec­es­sary to attract exter­nal investors. His busi­ness career is com­bined with an aca­d­e­mic role involv­ing teach­ing at the Fac­ulty of Polit­i­cal Sci­ence at War­saw Uni­ver­sity. He is the project man­ager and gen­eral exec­u­tive of R & D projects of the Min­istry of Sci­ence and Higher Edu­ca­tion and author and co-​author of sev­eral mono­graphs and sci­en­tific articles.

Media

  • media1
  • media2
  • media3
  • media4
  • media5
  • media6

Spon­sors

main patron

NCBR

hon­orary patronage

JCI
UJ

part­ners

deloitte parp

spon­sors

PZU Assign
incaptum TaylorWessing

media part­ner

Dolina Biotechnologicyna pharmaceutical representative
biotechnologia biocon
bio-partnerEUBIO bankierpl Life-Sciences-Europe iito ELSJ Jagiellonian University Technology Offer onenucleus laboratorium